J.P.Morgan cuts Agios PT after sickle cell drug setback
J.P.Morgan cuts PT on drugmaker Agios Pharmaceuticals AGIO.O to $20 from $37 after its sickle cell drug setback
New PT represents 10% downside to stock's last close
AGIO said on Wednesday its sickle cell disease drug, mitapivat, failed to show clear benefit in reducing painful crises, the debilitating pain episodes that are a hallmark of the condition, despite meeting its main target of improving blood levels in a late-stage trial
Brokerage adjusts revenue estimates for mitapivat to $28mln/$74mln/$155mln for 2026-2028
Have removed the "opportunity for mitapivat in SCD from our model" - brokerage
Three of 8 brokerages rate the stock "buy" or higher, 4 "hold" and 1 "sell"; median PT is $32 - data compiled by LSEG
Including session's moves, shares down ~29% YTD
Related Articles
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital ba
Cathie Wood Predicts Bitcoin Has Bottomed. Is Now The Best Time to Buy? How to Buy BTC?
Purchasing Bitcoin is generally divided into three stages: pre-transaction, during transaction, and post-transaction. Each stage requires careful attention, as losses can easily arise from operational errors, pitfalls, and other factors.
Musk’s Next Ambition: Building a Space-Based AI Data Center
TradingKey - Musk has long resisted the idea of taking SpaceX public. After the Tesla take-private drama and the resulting SEC penalties (which cost him the chairmanship), he’s been wary of public market entanglements. But something’s changed—and fast.
Japan Central Bank Rate Hike To Three-Decade High Imminent, How Will The Market Go? Which Assets Most Affected?
As global monetary policy divergence enters a critical phase, the Bank of Japan (BoJ) is anticipated to raise its benchmark interest rate at the monetary policy meeting on December 19, 2025, by 25 basis points to 0.75% , marking its highest level in nearly 30 years.
